

Saving lives by designing smart medical devices and sensing technologies

[PITCH VIDEO](#) [INVESTOR PANEL](#)

The image shows a pitch video thumbnail for Remosense. At the top, the company logo 'Remosense' is displayed with a blue signal icon above the 'o's. Below the logo is the tagline 'Advancing Digital Health with Precise Biomarkers' in blue text. A large red play button is centered over the text. Below the text, there are four images of the Remosense device: a hand holding a small white device, a white device with a blue top, a white device in its open carrying case, and a white device with a blue top and a small screen. At the bottom left, there is a navigation bar with the website 'telebionix.com', the location 'Los Angeles CA', and social media icons for Twitter, Facebook, and Instagram. At the bottom right, there are five category tags: 'Hardware', 'Software', 'Technology', 'Medical Device', and 'Social Impact'.

LEAD INVESTOR



Saimon Passannanti

Digital health has a huge potential to improve lives and extend medical services to underserved or unserved areas, and I am confident that the market and demand will only grow. For me, Remosense is an essential tool to accelerate digital health that offers benefits for patients and healthcare professionals, and organizations. It is great support for Physicians able to diagnose, treat and monitor patients remotely and an effective way to enhance the patient experience.

Invested \$3,000 this round

Highlights

- 1 Simple to use device that allows efficient and effective home care for your loved ones.
- 2 A perfect tool for health tracking and health data sharing from the comfort and safety of your home.
- 3 Brings the doctor to your home. safety of your home.
- 3 Brings the doctor to your home.
- 4 A unique product in the growing Telehealth market.
- 5 A visionary and experienced team at the forefront of R&D with proven industry track records.
- 6 \$485 Billion Opportunity with growing market verticals.

- 7 Remosense Cloud Compliant with FDA, CE Mark, HIPPA, GDPR, and ISO Certified.
- 8 The product is at the prototype stage and ready for mass production.

Our Team



Widy Medina Chief Executive Officer

An innovator with 25+ yrs of experience in robotics, product design, fabrication, automation to electronic assembly of consumer products, food and beverage tech, biotech, medical devices, and pharmaceutical industries.

We believe that healthcare is a human right and not a luxury for some. Remosense is the key to balance the scale and allow everyone true quality healthcare. The recent pandemic showed us exactly where the gaps were in our healthcare infrastructure. We are concentrating our efforts on filling one of those gaps with the best solution possible.



Aghiath Chbib Chief Operating Officer

Serial entrepreneur with experience co-founding three companies. An award-Winning expert in Cybersecurity. Recognized as one of the Top 50 Global Thought Leaders and Influencers. Advisory Board Member for the CEH (Certified Ethical Hacker).



Prof. Dr. Robert Bauernschmitt, MD Medical Research Advisor

Published medical professional and scientist specializing in cardiovascular surgery with over 20 years of experience based in University Hospital Zurich. Currently a member of the German Society of Thoracic and Cardiovascular Surgery.



Prof. Dr. med. Paul R. Vogt Cardiology Application Advisor

Founder of Euroasia Heart Foundation specializing in cardiovascular surgery with over 30 years of experience based in University Hospital Zurich Division of Cardiac Surgery. Currently a member of the European Society of Cardiothoracic Surgery.



Prof. Dr. Astrid Stuckleberger UN & WHO Liaison | PhD

Scientist, researcher, trainer, author in international health and health for all. Ph.D., Privat-Dozent at the Faculty of Medicine of the University of Geneva and Lausanne. Top Swiss researcher and teacher for 20 years.



Prof. Dr. med Samer Ellahham, MD Medical Technology & AI ApplicationsAdvisor | MD

Physician healthcare executive with a proven ability to transform healthcare systems. Senior Cardiology Consultant, Heart, and Vascular Institute and Director of Accreditation, Quality and Patient Safety Institute, Cleveland Clinic Abu Dhabi



Chris Baines Financial Advisor

35 years of international and regional investment banking experience at leading houses encompassing structured debt, equity capital markets, and direct lending fund management.



Jaime Vaquer Life Sciences Advisor | PhD

Senior life sciences professional driven by six sigma and lean manufacturing philosophies with over 25 years of experience.



Barbara Perez Corporate Liaison Officer

Creative problem solver with a high work ethic, professionalism who loves working with people. Passionate copywriter and MBA student at Pepperdine University.



Frederico Fernandes Investment & Partnerships Advisor

Currently, head of Global Markets at Prevention, Start-Up Mentor and Intelak Hub, and Co-Founder of NewsAvia, an online media company. He brings the investor, customer, and partners' perspectives to the organization.

Pitch




Introduction Summary - Focused and results driven from inception

Who are we?

Telebionix is a privately-held California-based medtech company building AI-



enabled, smart medical devices designed for the post-covid healthcare landscape. Our flagship device, Remosense, is an all-in-one, clinical grade remote patient monitoring system that allows telemedicine patients to relay key vital signs to their doctor without leaving their homes.



Business Model

- Device Sales
 - B2B
- Licensing Models
 - Recurring fees

\$485 Billion

Opportunity with growing market verticals.

Key Investment Considerations

Investment Ask

\$1M

Assumptions: Exit

Value **1B**

Forward-looking projections cannot be guaranteed.

OPPORTUNITY

Remote Healthcare Challenges



Telehealth services are scaling faster than ever, yet doctors lack the effective, accurate and reliable pre-screening equipment at the patient side to provide a precise diagnostic.

Result:

- Ineffective consultations = Loss of Engagement
- Unnecessary visits to ERs =
- Misdiagnosis
- Poor user experiences

Current alternatives require separate devices, that are costly and disconnected from healthcare services.

SOLUTION

Convenient, Low-Cost, Smart



Our solution is Remosense; a portable system designed to capture and deliver medical-grade vital sign information:

- Body Temperature
- Blood Pressure
- Heart Rate (RR)
- Heart Rate Variability (RRI)
- Blood Oxygenation level (SpO2)
- ECG
- AI Driven Digital Stethoscope
 - Lung Sounds
 - Heart Sounds

Providing accurate and secure information for effective healthcare.

Confidential & Proprietary

3

telebionix

Market Opportunity - A \$485 Billion Opportunity with growing market verticals.

\$485 Billion



\$250B Telehealth Market Projection
Valued by McKinsey (2020)



38.2% CAGR growth rate in telehealth
by 2025 Frost & Sullivan (2020)



\$117B Remote Patient Monitoring
Market Projection by 2025 (2020)



\$72B Personal Health Tracking
Market Valuation by 2022 (2017)



\$46.6B Wearable Healthcare Devices
Market Projection by 2025 (2020)

Growing global acceptability of telehealth programs.

90% of healthcare executives say their organizations are developing or already have a telehealth application.

75% of all doctor, urgent care, and ER visits "are either unnecessary or could be handled safely and effectively over the phone or video"

For reference information please see slide ## for links.

4

telebionix

Remosense Intro Video

Watch later
 Share

Watch on  YouTube

Remosense Product Use Simple to use, extremely reliable, and secure by design.



Confidential & Proprietary

6

telebionix

Remosense Product Use Accurate, Precise and Repeatable information for better remote care while collecting and storing information for ongoing monitoring.




Confidential & Proprietary

7


telebionix

How does it work - Seamless connectivity and secure information transfer





Remosense Cloud Framework - Secure, Compliant & Scalable Connectivity




Remosense Artificial Intelligence - Application & Mission

An exceptional device Powered by next-generation AI.

Application

Gathering biomarker data with accuracy & repeatability:

1. Heart Rate
2. Blood Pressure
3. Body Temperature
4. Blood Oxygenation
5. Heart Rate Variability
6. ECG
7. Stethoscope
 - Lung Sounds
 - Heart Sounds



Mission

Consolidating biomarker data coupled with professional diagnostic labels creates a unique data set; when correlated using AI will create a powerful analysis that will evolve into a predictability model in the future.



Remosense Value Proposition by Market Channel

We have spoken to six potential customers in the EMEA region, the USA, and Canada; here is why they are thrilled about us.

| Hospitals | Telehealth Service Providers | Doctors and Patients |
|---|---|---|
| <ul style="list-style-type: none"> Assist cost savings of 64% on in-hospital vs Telehealth visits, while keeping quality biomarkers data. Improves quality of Healthcare Service and diagnostics Improves patient engagement with remote monitoring Expands access to care and reaches more patients Improves Practice Efficiency Reduces Human error | <ul style="list-style-type: none"> Increase revenue with units and service sales Expands Doctors diagnostic capabilities Enhance users and Doctor's experience Seamless Integration Expands access to care and reaches more patients Streamlined Telehealth Process | <ul style="list-style-type: none"> Leverages Telehealth savings without compromising on accuracy of biomarkers data Increases practice revenue Reduces practice overhead Reduces patient no-shows Improves healthcare quality Improves precise diagnostic Improves patient satisfaction |

[Reference Link](#)



Remosense Distribution Channels and Users

How?

Leveraging single points of sale and distribution channels. Telehealth providers HMOs



Telebionix



Healthcare Providers



Doctors & Practices



Medical Patients



Why?

Direct access to the market with minimal sales effort.

Confidential & Proprietary

12

telebionix

Remosense Product Roadmap

Staying ahead of the competition through constant product innovation and enhancement.

Remosense

V1

1. Heart Rate
 2. Blood Pressure
 3. Body Temperature
 4. Blood Oxygenation
 5. Heart Rate Variability
 6. ECG
 7. AI Driven Stethoscope
- Lung Sounds
Heart Sounds



2021

Remosense

Interconnection Platform

1. Complete Modalities AI Correlation
2. APIs
3. Blockchain DB Standard



2022



V2

1. Integrated touchscreen
2. Front facing camera
3. Hands free biomarker reading

2022-2023



V3

- Additional Modalities:
1. Voice-audio Diagnostics
 2. Glucose Sensors
 3. Eye-fundus Imagery
 4. Ultra-sound

2023-2024

telebionix

Forward-looking projections cannot be guaranteed.

Remosense Recognitions & Awards

SUPERNOVAS Feature in RedCrow (2021)



openbusiness council awards

Digital Wellness & Healthtech Award (2021)



Top 50 Healthcare Companies Award (2021)

Most Fundable Companies* PEPPERDINE

Semi Finalist* to Most Fundable Companies Competition (2021)
*Actively Competing To Finals

Top 5 Trending Companies in RedCrow (2021) (four consecutive weeks)



14

telebionix

Remosense Ecosystem & Traction - Valuable partnerships, MOU, and LOI

Government Support

Direct support from the Small Business Development Centre (SBD) in:

- International Trade Support
- Manufacturing Assistance
- Regulatory Compliance Support

World Humanitarian Forum

Partnering with the WHF will expose Remosense to multiple NGOs and find ways Remosense can collaborate with their mission to save lives that align with our purpose.

- Access to UNESCO and health organizations
- Support to provide refugee camps with better healthcare.

University R&D Collaboration

This strategic partnership allows for fast-track product development in multiple areas:

- Additional modality development
- Technology roadmap deployment
- Cutting edge voice diagnostics research

Distribution Channel Partners

Business Development and distribution partner for the following regions:

- USA & Canada
- Middle East

Ongoing discussions with a Telehealth provider for U.S. Department of Veterans Affairs to define use cases and technical integrations with their platform.

Also, initiated discussions with government entity in Saudi Arabia to assess product fit and use cases.

Confidential & Proprietary

15



Our Team

Years of Experience

Collectively we bring to the company 250+ years of professional experience in IT, AI, Robotics, Cybersecurity, Medical Devices, Pharmaceuticals, Medical Care, Public Health, Investment Banking and other industries

Education

70% of our team have Ph.D. level expertise in medicine, scientific research and product development.

Track Record

The team comes with a proven track record of successful technological product development in some of the following top global companies.



Confidential & Proprietary

16



Leadership Team



Widy Medina
Co-Founder & CEO

Over 25 years of product design and manufacturing experience. Entrepreneur with successful exits.



Aghiath Chbib
Co-Founder & COO

Over 20 Years of Cybersecurity Experience, thought leader and top influencer. Entrepreneur with successful exits



Ali Alamdari, Ph.D.
Director of R&D

Mechatronics and Product Design Expert. Successful product launch for top e-commerce platform



Mostafa Ghobadi, Ph.D.
VP of Eng.

Product Design and Product Architecture Expert. Successful product launch for high-end product lines.

Confidential & Proprietary

17



Advisory Board



Prof. Dr. David Bell



Prof. Dr. David Bell



Prof. Dr. David Bell



Prof. Dr. David Bell

Prof. Dr. med. Paul K. Vogt,
Cardiology Application
Advisor

Prof. Dr. med. Robert
Bauernschmitt,
Medical Research Advisor

Prof. Dr. med. Samer
Ellaham, MD,
Medical AI Tech. Advisor

Prof. Dr. Astrid Stuckeberger
UN & WHO Liaison



Jaime Vaquer, Ph.D.
Life Sciences Advisor



Chris Baines
Financial Advisor



Frederico Fernandes
Investment &
Partnerships Advisor

Confidential & Proprietary

18



Funding Raised & Ask

Investment Ask: **\$1M**

Pre-money valuation:
\$8M


Self-funded: **\$350K**
Prototype For Mass
Productions Complete



Medical Trial, IP, & Patent

FDA Approval

Sales & Marketing



Confidential & Proprietary

19



When passion meets opportunity, anything is possible

telebionix

Thank you.



Widy Medina, CEO

wmedina@telebionix.com

Aghiath Chbib, COO

achbib@telebionix.com

Confidential & Proprietary

20

telebionix

Downloads

[IFAH-Award.png](#)

[Open-Council-Award-2048x1448.jpg](#)